News & Updates

A retrospective analysis has shown that increasing the dose of subcutaneous infliximab (CT-P13 SC) from 120 to 240 mg Q2W in patients with inflammatory bowel disease who initially responded but subsequently lost response leads to improved clinical efficacy over an extended period.

Treatment with colchicine appears to lower the risk of stroke and major adverse cardiovascular events (MACE) when used for longer duration, according to a study presented at ISC 2025. This beneficial effect, however, is not observed among patients with shorter follow-up duration.

The postpartum use of diuretics can reduce persistent hypertension in women with hypertensive disorders of pregnancy (HDP), according to the results of a systematic review and meta-analysis presented at SMFM 2025.